Clinical Trial

Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 22, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to evaluate the efficacy and safety of Iparomlimab and tuvonralimab (QL1706) in combination with platinum-based chemotherapy for cervical cancer neoadjuvant therapy. Additionally, the study aims to identify potential predictive biomarkers for therapeutic efficacy by analyzing tumor tissues and peripheral blood samples from participants receiving this combined treatment regimen.
Trial Details
NCT Number NCT06986057
Lead Sponsor Shandong Tumor Hospital
Conditions Cervical Cancer, Neoadjuvant Therapy
Enrollment 28 participants
Start Date 2025-05-31
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-22